The U.S. Congressional Research Service (CRS) recently issued a report that provides a “background on pharmaceutical supply chain security and a discussion of policy considerations” against a backdrop of congressional efforts to adopt measures that would protect patients and manufacturers. Titled “Pharmaceutical Supply Chain Security,” the report contains an overview of the types of interventions Congress is considering, including track and trace, standardized numerical identifiers, lot- or unit-based approaches, technology choices, interoperability requirements, data management and access, confidentiality, accountability, costs, and federal/state jurisdiction. CRS concludes that as the supply chain shifts to a global network of manufacturers, processers, packagers, importers, and distributors, it becomes more important to find a way to “keep counterfeit, mishandled and substandard drugs away from patients.”